NCT04569214撤回2 期
A Comparative, Dose-Escalating, Placebo-Controlled Study of the Efficacy and Safety of PAZ320, Ingested Together With a Standard Meal on Post-Prandial Glucose and Insulin Blood Levels in Type II Diabetic Patients Treated With Metformin
Boston Therapeutics1 个研究点 分布在 1 个国家开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.
研究概览
简要总结
The purpose of this study is to test the efficacy of PAZ320 in diabetic patients.
详细描述
The purpose of the present clinical study is to test the efficacy of two doses of PAZ320 in diabetic patients already on treatment with metformin, in order to assess and quantify its effect on postprandial glucose and insulin levels after a standard meal composed of rice, compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with type II diabetes since at least one year, not presenting any complications of their disease.
- •Patients under treatment with Metformin up to 3g/day, given twice or three times daily. Metformin doses should not exceed 3g/day, and should be well tolerated by the patients, its dose should have been stable for the last 3 months before inclusion in the study. Metformin should be taken in the morning of the visit only after the test meal is taken. The next doses of metformin will be taken with meals after the visit, in the habitual order the patient is used to take. The patients should not stop taking metformin during the study, but continue as usual, except that in the mornings of the visits, as the patients arrive in fasting conditions, metformin should be taken after the test meal. If a concomitant combination with an oral anti diabetic agent is given, because of elevated HbA1c levels, it should be taken together with metformin after the test meal.
- •Age - between 35 and 65, male and female.
- •Females should not be pregnant or breast feeding, women of child bearing potential should guarantee anti-contraceptive measures.
- •BMI (body mass index) - between 25 and
- •Patients with glycated hemoglobin (HbA1c) lower than 9%, and higher than 6.5%, HbA1c will be determined in the first visit.
- •Patients who are able to collaborate during the entire duration of the study.
排除标准
- •Patients with other underlying diseases, such as cardiovascular disease, renal disease, peripheral vascular disease or any condition considered to be a complication of diabetes, should be excluded from this study.
- •Patients treated with insulin subcutaneous injections or with GLP-1 agonists, or by alpha-glucosidase inhibitors or by glinides should not be included in the study.
- •HbA1c higher than 9%, or lower than 6.5%
- •Women who are either pregnant or lactating
- •Participation in another clinical study in the month preceding recruitment into the study.
- •Patients who cannot guarantee compliance.
研究组 & 干预措施
A - Placebo Control
Placebo Comparator
4 tablets of placebo
干预措施: Placebo (Other)
B - PAZ320 Low Dose
Experimental
2 tablets of PAZ320 and 2 tablet of placebo
干预措施: PAZ320 (Drug)
B - PAZ320 Low Dose
Experimental
2 tablets of PAZ320 and 2 tablet of placebo
干预措施: Placebo (Other)
C - PAZ320 High Dose
Experimental
4 tablet of PAZ320
干预措施: PAZ320 (Drug)
结局指标
主要结局
Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.
时间窗: 2 weeks
The extent and duration of PAZ320 effect on postprandial blood glucose levels in type II diabetic patients will be assessed under treatment with metformin, over 4 hours after the intake of a standard meal, using an implanted continuous glucose monitoring device.
次要结局
- Number of Subjects with Adverse Events as a Measure of Safety and Tolerability(2 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary DiseaseNCT00758706AstraZeneca55
已完成
2 期
A Study of LY2409021 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01241448Eli Lilly and Company263
已完成
2 期
Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 DiabetesType 2 Diabetes Treated With InsulinNCT02060916Boston Therapeutics24
已完成
2 期
Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyDiabetic Macular EdemaNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT04692688Ocuphire Pharma, Inc.103
已完成
不适用
To Assess the Efficacy of Investigational Product on the Neuropathic Pain in Individuals Suffering From Type II Diabetes Mellitus.Diabetic NeuropathiesInsomnia Due to Medical ConditionNCT04504305Vedic Lifesciences Pvt. Ltd.64